ReviewMolecules (Basel, Switzerland)2026
Engineering Strategies of Colloidal Drug Delivery Systems, a Rising Star in Ocular Neovascular Diseases.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ocular neovascular diseases represent a major cause of irreversible vision loss worldwide, while the complex ocular barrier system significantly limits the efficacy of conventional treatment approaches. In this context, colloidal drug delivery systems (CDDSs) have emerged as an innovative nanomedicine strategy that demonstrates remarkable advantages in enhancing ocular drug bioavailability and treatment precision through the integration of sustained release, active targeting, and stimulus-responsive functional modules. This review systematically summarizes recent research advances in CDDSs for treating ocular neovascular diseases, with a particular focus on design strategies and mechanisms for overcoming physiological barriers and achieving lesion-specific drug delivery. Furthermore, it provides in-depth analysis of key challenges in current clinical translation. With ongoing technological advancements, CDDSs are expected to offer breakthrough solutions for treating ocular neovascular diseases, ultimately leading to significant improvements in patients' visual prognosis and quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.